1 |
Kapiotis S, Hermann M, Held I, Seelos C, Ehringer H, Gmeiner BM. 1997. Genistein, the dietary-derived angiogenesis inhibitor, prevents LDL oxidation and protects endothelial cells from damage by atherogenic LDL. Arterioscler Thromb Vasc Biol 17: 2868-2674
DOI
ScienceOn
|
2 |
Ruiz-Larrea MB, Mohan AR, Paganga G, Miller NJ, Bolwell GP, Rice-Evans CA. 1997. Antioxidant activity of phytoestrogenic isoflavones. Free Radic Res 26: 63-70
DOI
ScienceOn
|
3 |
Sargeant P, Farndale RW, Sage SO. 1993. The tyrosine kinase inhibitors methyl 2,5-dihydroxycinnimate and genistein reduce thrombin-evoked tyrosine phophorylation and entry in human platelets. FEBS Letters 315: 242 -246
DOI
ScienceOn
|
4 |
King RA, Bursill DB. 1998. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am J Clin Nutr 67: 867-872
DOI
|
5 |
Jarred RA, Keikha M, Dowling C. 2002. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev 11: 1689-1696
|
6 |
Wilcox JN, Blumenthal BF. 1995. Thrombotic mechanisms in atherosclerosis: potential impact of soy protein. J Nutr 125: 631S-638S
|
7 |
Akiyama T, Ishida J, Nakagava S, Ogawara S, Watanabe S, Itoh N, Shiyba M, Fukami Y. 1987. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262: 5592-5595
|
8 |
Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. 2001. Interleukin-6 and prostate cancer progression. Cytokine & Growth Factor Reviews 12: 33-40
DOI
ScienceOn
|
9 |
Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. 1999. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 161: 182-187
DOI
ScienceOn
|
10 |
Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. 1999. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41: 127-133
DOI
ScienceOn
|
11 |
Jones A, Fujiyama C, Turner K, Fuggle S, Cranston D, Bicknell R, Harris AL. 2000. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int 85: 276-280
DOI
ScienceOn
|
12 |
Lucia MS, Torkko KC. 2004. Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J Urol 171: S30-S35
DOI
ScienceOn
|
13 |
Duque JLF, Loughlin KR, Adam RM. 1999. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54: 523- 527
DOI
ScienceOn
|
14 |
Turner K, Jones A. 2000. Vascular endothelial growth factor in prostate cancer. Urology 56: 183
|
15 |
Kollermann J, Helpap B. 2001. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. Am J Clin Pathol 116: 115-121
DOI
ScienceOn
|
16 |
Davis JN, Kucuk O, Djuric Z, Sarkar FH. 2001. Soy isoflavone supplementation in healthy men prevents NF- kappa B activation by TNF-alpha in blood lymphocytes. Free Radic Biol Med 30: 1293-1302
DOI
ScienceOn
|
17 |
Li Y, Upadhyay S, Bhuiyan M, Sarkar FH. 1999. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 18: 3166-3172
DOI
ScienceOn
|
18 |
Morris SM, Chen JJ, Domon OE, McGarrity LJ, Bishop ME, Manjanatha MG, Casciano DA. 1998. P53, mutation and apoptosis in genistein-exposed human lymphoblastoid cells. Mutat Res 405: 41-56
DOI
ScienceOn
|
19 |
Salti GI, Grewal S, Mehta RR, Das Gupta TK, Boddie AW, Constantinou AI. 2000. Genistein induces apoptosis and topoisomerase Π-mediated DNA breakage in colon cancer cells. Eup J Cancer 36: 796-802
DOI
ScienceOn
|
20 |
Traganos F, Ardelt B, Halko N, Bruno S, Darzynkiewicz Z. 1992. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res 52: 6200- 6208
|
21 |
Miltyk W, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, Lopaczynski W, Mahoney C, Jeffcoat RA, Crowell J, Paglieri J, Zeisel SH. 2003. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 77: 875-882
DOI
|
22 |
Mitchell JH, Collins AR. 1999. Effects of a soy milk supplement on plasma cholesterol levels and oxidative DNA damage in men-a pilot study. Eur J Nutr 38: 143-148
DOI
ScienceOn
|
23 |
Djuric Z, Chen G, Doerge DR, Heilbrun LK, Kucuk O. 2001. Effect of soy isoflavone supplementation on markers of oxidative stress in men and women. Cancer Letters 172: 1-6
DOI
ScienceOn
|
24 |
Messina MJ, Persky V, Setchell KD, Barnes S. 1994. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 21: 113-131
DOI
ScienceOn
|
25 |
Affenito SG, Kerstetter J. 1999. Position of the American dietetic association and dietitians of Canada: women's health and nutrition. J Am Diet Assoc 99: 738-751
DOI
ScienceOn
|
26 |
Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y. 1987. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262: 5592-5595
|
27 |
Davis JN, Muqim N, Bhuiyan M, Kucuk O, Pienta KJ, Sarkar FH. 2000. Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. Int J Oncol 16: 1091-1097
|
28 |
Wang W, Goodman MT. 1999. Antioxidant property of dietary phenolic agents in a human LDL-oxidation ex vivo model: interaction of protein binding activity. Nutr Res 19: 191-202
DOI
ScienceOn
|
29 |
Huang MH, Harrison GG, Mohamed MM, Gornbein JA, Henning SM, Go VLW, Greendale GA. 2000. Assessing the accuracy of a food frequency questionnaire for estimating usual intake of phytoestrogens. Nutrition and Cancer 37: 145-154
DOI
ScienceOn
|
30 |
Korea National Statistical Office. 2003. Annual report on cause of death statistics
|
31 |
Adlercreutz H, Mazur W, Bartels P, Elomaa V, Watanabe S, Wahala K. 2000. Phytoestrogens and prostate disease. J Nutr 130: 658S-659S
DOI
|
32 |
DiPaola RS, Zhang H, Lambert GH, Meeker R, Licitra E, Rafi MM. 1998. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 339: 785-791
DOI
ScienceOn
|
33 |
Cao Y, Chen H, Zhou L, Chiang MK, Anand-Apte B, Weatherbee JA, Wang Y, Fang F, Flanagan JG, Tsang ML. 1996. Heterodimers of placenta growth factor/vascular endothelial growth factor. J Biol Chem 271: 3154-3162
DOI
|
34 |
Rojas E, Lopez MC, Valverde M. 1999. Single cell gel electrophoresis assay: methodology and applications. J Chromatography B 722: 225-254
DOI
ScienceOn
|
35 |
Messina MJ. 2003. Emerging evidence on the role of soy in reducing prostate cancer risk. Nutr Rev 61: 117-131
DOI
|
36 |
Onozawa M, Fukuda K, Ohtani M, Akaza H, Sugimura T, Wakabayashi K. 1998. Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP. Jpn J Clin Oncol 28: 360-363
DOI
ScienceOn
|
37 |
Claffey KP, Robinson GS. 1996. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev 15: 165-176
DOI
ScienceOn
|
38 |
Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. 1995. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45: 542-549
DOI
ScienceOn
|
39 |
Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. 1999. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41: 127-133
DOI
ScienceOn
|
40 |
Ferrara N, Davis-Smith T. 1997. The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25
DOI
ScienceOn
|
41 |
Torel J, Cillard J, Cillard P. 1986. Antioxidant activity of flavonoids and reactivity with peroxy radical. Phytochemistry 25: 383-385
DOI
ScienceOn
|
42 |
Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. 1993. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidants status in premature neonates. Clin Sci 84: 407-412
DOI
|
43 |
Hansen MB, Svenson M, Diamant M, Bendtzen K. 1993. High-affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro. Cytokine 5: 72-80
DOI
ScienceOn
|
44 |
Miller NJ, Castellucio C, Tijburg L, Rice-Evans C. 1996. The antioxidant properties of theaflavins and their gallate esters-radical scavengers or metal chelators. FEBS Letters 392: 40-44
DOI
ScienceOn
|
45 |
Rice-Evans C, Miller NJ. 1994. Total antioxidant status in plasma and body fluids. Methods Enzymol 234: 279-293
DOI
|
46 |
Sachez-Rodriguez M, Mendoza-Nunez VM, Vargas-Guadarrama LA. 1998. Niveles de antioxidantes totales en una muestra de la poblaci?n gerontol?gica de la ciudad de Mexico. Bioquimia 23: 848-855
|
47 |
MacEwan DJ. 2002. TNF ligands and receptors - a matter of life and death. British J Pharmacology 135: 855-875
DOI
ScienceOn
|
48 |
Kirk EA, Sutherland P, Wang SA, Chait A, LeBoeuf RC. 1998. Dietary isoflavones reduce plasma cholesterol and atherosclerosis in C57BL/6 mice but not LDL receptor- deficient mice. J Nutr 128: 954-959
DOI
|
49 |
Urban D, Irwin W, Kirk M, Markiewicz MA, Myers R, Smith M, Weiss H, Grizzle WE, Barnes S. 2001. The effects of isolated soy protein in plasma biomarkers in elderly men with elevated serum prostate specific antigen. J Urol 165: 294-300
DOI
ScienceOn
|
50 |
Jenkins DJ, Kendall CW, D'Costa MA, Jackson CJ, Vidgen E, Singer W, Silverman JA, Koumbridis G, Honey J, Rao AV, Fleshner N, Klotz L. 2003. Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men. J Urol 169: 507-511
DOI
ScienceOn
|